secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001213900-22-070134
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics Q3 net loss widens to $3.0M; cash $13.3M; FDA submission planned H1 2023
--------------------------------------------------------------------------------

- Net loss for Q3 2022 was $3.0M ($0.15 per share) vs $1.2M ($0.11 per share) in Q3 2021.
- Cash and cash equivalents at Sep 30, 2022: $13.3M, down from $19.0M at Dec 31, 2021; cash expected to fund operations for 12 months.
- R&D expenses rose to $1.4M in Q3 2022 from $443k in Q3 2021 due to clinical program expansion and scale-up manufacturing.
- No product sales in Q3; small non-recurring sale in Q2 2022 generated ~$250k revenue for nine months.
- Company plans to submit De Novo application for Symphony IL-6 test with FDA in first half of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390022070134/0001213900-22-070134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390022070134/ea168158-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-070134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer